Safety of treatment and dietary Supplementation with dioSmin in daily doSeS up to 2000 mg a day

Q4 Medicine New Medicine Pub Date : 2016-09-29 DOI:10.5604/14270994.1222599
Agnieszka Staniewska
{"title":"Safety of treatment and dietary Supplementation with dioSmin in daily doSeS up to 2000 mg a day","authors":"Agnieszka Staniewska","doi":"10.5604/14270994.1222599","DOIUrl":null,"url":null,"abstract":"Introduction. diosmin is used to treat and alleviate the symptoms of venous insufficiency and haemorrhoids. diosmin-containing medicinal products have been available in poland since the 1990s with the status of drugs available on prescription in the form of flavonoid fraction containing diosmin, as a form subjected to micronisation or nonmicronised. for several years now, diosmin has been present on the pharmaceutical market in the form of over-the-counter medicines (otC), and dietary supplements containing diosmin are available not only in pharmacies, but also in other outlets. great availability of diosmin raises questions about the safety of a treatment without medical or pharmacist’s supervision. the safety of diosmin use in a daily dose of 2000 mg was confirmed in a double-blind, controlled placebo, randomised, three-arm and parallel, phase iii to evaluate the efficacy and safety of diosmin administered for 4 months in the treatment of cellulite. Aim. the aim of the study was to observe the efficacy and safety of micronised diosmin therapy used in a daily dose of 1000 and 2000 mg for a period of four months. Material and methods. the trial involved 327 patients aged 18 to 55 (mean 37.28, standard deviation of 8.587) meeting the inclusion criteria and not meeting the exclusion criteria. the safety analysis includes and shows in a table the measured parameters immediately prior to the first dose, after 2 and 4 months of therapy. Results. no statistically significant deviations from the standard condition in the following parameters present: complete blood count with differential, fibrinogen concentrations, alanine and aspartate transaminase concentration, urea and creatinine concentration, urinalysis. the therapy did not affect the value of systolic and diastolic blood pressure. no significant adverse actions in the studied groups. Conclusions. the results of a clinical trial cited in this work support the use of micronised diosmin in doses up to 2000 mg per day.","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"20 1","pages":"61-68"},"PeriodicalIF":0.0000,"publicationDate":"2016-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5604/14270994.1222599","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

Abstract

Introduction. diosmin is used to treat and alleviate the symptoms of venous insufficiency and haemorrhoids. diosmin-containing medicinal products have been available in poland since the 1990s with the status of drugs available on prescription in the form of flavonoid fraction containing diosmin, as a form subjected to micronisation or nonmicronised. for several years now, diosmin has been present on the pharmaceutical market in the form of over-the-counter medicines (otC), and dietary supplements containing diosmin are available not only in pharmacies, but also in other outlets. great availability of diosmin raises questions about the safety of a treatment without medical or pharmacist’s supervision. the safety of diosmin use in a daily dose of 2000 mg was confirmed in a double-blind, controlled placebo, randomised, three-arm and parallel, phase iii to evaluate the efficacy and safety of diosmin administered for 4 months in the treatment of cellulite. Aim. the aim of the study was to observe the efficacy and safety of micronised diosmin therapy used in a daily dose of 1000 and 2000 mg for a period of four months. Material and methods. the trial involved 327 patients aged 18 to 55 (mean 37.28, standard deviation of 8.587) meeting the inclusion criteria and not meeting the exclusion criteria. the safety analysis includes and shows in a table the measured parameters immediately prior to the first dose, after 2 and 4 months of therapy. Results. no statistically significant deviations from the standard condition in the following parameters present: complete blood count with differential, fibrinogen concentrations, alanine and aspartate transaminase concentration, urea and creatinine concentration, urinalysis. the therapy did not affect the value of systolic and diastolic blood pressure. no significant adverse actions in the studied groups. Conclusions. the results of a clinical trial cited in this work support the use of micronised diosmin in doses up to 2000 mg per day.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
治疗和膳食补充的安全性,每日剂量高达2000mg /天
介绍。地奥司明用于治疗和缓解静脉功能不全和痔疮的症状。自20世纪90年代以来,波兰已提供含薯蓣皂苷的医药产品,其处方药物状态为含有薯蓣皂苷的类黄酮部分,作为微粉化或非微粉化的形式。几年来,戴奥司明已经以非处方药(otC)的形式出现在医药市场上,含有戴奥司明的膳食补充剂不仅在药店,而且在其他渠道也可以买到。在没有医生或药剂师监督的情况下,地奥明的大量可用性引发了对治疗安全性的质疑。在一项双盲、对照安慰剂、随机、三组平行、iii期研究中,日剂量为2000mg的地奥司明的安全性得到了证实,该研究旨在评估地奥司明治疗脂肪团4个月的疗效和安全性。的目标。这项研究的目的是观察在4个月的时间里,每日剂量为1000和2000毫克的微型二恶英治疗的疗效和安全性。材料和方法。试验纳入327例符合纳入标准和不符合排除标准的患者,年龄为18 ~ 55岁(平均37.28,标准差8.587)。安全性分析包括并在表格中显示了在第一次给药前、治疗2个月和4个月后测量的参数。结果。以下参数与标准条件无统计学差异:全血细胞计数差异、纤维蛋白原浓度、丙氨酸和天冬氨酸转氨酶浓度、尿素和肌酐浓度、尿液分析。治疗不影响收缩压和舒张压值。在研究组中没有明显的不良反应。结论。这项工作中引用的一项临床试验结果支持每天使用高达2000毫克的微细化地奥米明。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
New Medicine
New Medicine Medicine-General Medicine
CiteScore
0.10
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊介绍: - New Medicine is indexed in Index Copernicus (IC value 6.60) and registered in Embase/Excerpta Medica. - It is published in English and some issues in other languages. - New Medicine covers a broad spectrum of disciplines. - New Medicine is sent to national and medical libraries in several countries all over the world and to some libraries and institutions in Poland. It is also present on medical conferences. - New Medicine is published under the patronage of Polish Society of Health Education.
期刊最新文献
Dental caries in primary teeth during early childhood in the Warsaw agglomeration Mediastinal emphysema as a complication of posterior pharyngeal wall injury – a case report Abscess and hematoma of the septum – old diagnosis, contemporary treatment options Caries distribution pattern in primary dentition in children in early childhood from the Warsaw agglomeration The innovative laryngological cannula facilitates the precise collection of highly diagnostic material from the nose and sinuses in order to improve the diagnostic and therapeutic process
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1